Corvus Pharma Q1 net loss $8.3M; cash $62.9M; Phase 2 NSCLC trial planned

Corvus Pharmaceuticals, Inc.

2022-Q1 EPS reported -$0.18

Net loss $8.3M for Q1 2022 vs $11.6M in Q1 2021; R&D expenses down to $5.1M from $8.2M.
Cash, cash equivalents and marketable securities $62.9M as of March 31, 2022 vs $69.5M at Dec 31, 2021.
Plans Phase 2 randomized trial of mupadolimab + chemo in front-line NSCLC in 2022 with ~150 patients.
Phase 1b/2 ciforadenant + ipilimumab/nivolumab in front-line RCC to start Q3 2022 via Kidney Cancer Consortium.
Phase 1/1b CPI-818 (ITK inhibitor) continues enrolling T-cell lymphoma patients; data expected later 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.